15 Dividend Stocks to Buy for Steady Income

10. Johnson & Johnson (NYSE:JNJ)

Dividend Yield as of March 19: 2.18%

On March 19, Barclays raised its price recommendation on Johnson & Johnson (NYSE:JNJ) to $234 from $217. It kept an Equal Weight rating on the shares. The firm said its analysis confirms the company’s “strong” 23% US pharma growth excluding Stelara in Q4 is carrying into Q1. Growth is coming from both established products and newer franchises in the US. Barclays increased its estimates following that trend.

On March 12, the company announced U.S. Food and Drug Administration approval of TECNIS PureSee IOL, an extended depth of focus intraocular lens designed for cataract surgery. The company said the lens delivers clear vision, with 97% of patients reporting no very bothersome visual disturbances. TECNIS PureSee IOL is expected to become available in the U.S. later this year.

The product adds to Johnson & Johnson’s surgical vision portfolio, which builds on 25 years of intraocular lens innovation. Each year, millions of patients globally receive TECNIS lenses as part of cataract procedures.

Johnson & Johnson (NYSE:JNJ) operates across a wide range of healthcare products through two segments: Innovative Medicine and MedTech.